Back to today’s briefing

Story perspectives

FDA Approves 20 New Drugs, Fuels Cost Reform Efforts

7/20/2025

25 3

Summary

Story summary

In 2025, the FDA greenlit 20 new drugs, sparking a wave of legislative efforts to reduce prescription costs and reshape benefit plans. The emergence of biosimilars and GLP-1 therapies adds complexity to cost management. PharmaLogic® steps in with analytics to enhance pharmacy benefits and promote better population health outcomes.

1 of 1

Story summary

In 2025, the FDA greenlit 20 new drugs, sparking a wave of legislative efforts to reduce prescription costs and reshape benefit plans. The emergence of biosimilars and GLP-1 therapies adds complexity to cost management. PharmaLogic® steps in with analytics to enhance pharmacy benefits and promote better population health outcomes.